| Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b. | |
| | |
MedLine Citation:
|
PMID: 11721129 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The objective of this study was to investigate the effect of interferon (IFN) beta-1b on the serum levels of soluble tumor necrosis factor receptor 1 (sTNF-R1) and sTNF-R2 in patients with multiple sclerosis (MS) in correlation with clinical and magnetic resonance image (MRI) activity. Serum samples were obtained every 3 months from 24 patients treated with 8 x 10(6) U of IFN beta-1b every other day (treatment group) and from 21 patients without any immunomodulatory therapy (control group) over a 15-month observation period. The cytokine receptor levels were assessed by ELISA. Cranial MRI was performed every 6 months to determine the burden of disease. In the treatment group, the MRI responders had significantly larger mean values for the area under the concentration-time curve of sTNF-R1 (p = 0.04) and sTNF-R2 (p = 0.01) when compared to the MRI nonresponders during the 15-month observation period. With regard to an increase in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment, we observed a sensitivity of 33 and 58%, respectively, a specificity of 90 and 60%, respectively, and a positive predictive value of 80 and 64%, respectively, for MRI response during the 15-month observation period. A decrease in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment had a sensitivity of 40 and 20%, respectively, a specificity of 100 and 100%, respectively, and a positive predictive value of 100 and 100%, respectively, for further MRI nonresponse (during the 15-month observation period). The present data suggest that assessment of sTNF-Rs may contribute to the identification of subgroups of patients who are likely to respond better than others to treatment with IFN beta-1b. This could help to establish a cost-effective prescription pattern for this expensive treatment, which is of importance for the future management of patients with MS. |
| | |
Authors:
|
C Laske; P Oschmann; J Tofighi; B S Kühne; H Diehl; T Bregenzer; J Kraus; N Chatzimanolis; R Bauer; H Traupe; M Kaps |
Related Documents
:
|
20375729 - Tailoring treatment duration to 12 to 16 weeks in hepatitis c genotype 2 or 3 with rapi... 6197229 - Changes in serum proteins following implantation of pacemakers. 10690609 - Management of patients with hcv infection poorly tolerant to recombinant interferon alpha. 20691049 - Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 malaw... 12545079 - Hiv rna in plasma rebounds within days during structured treatment interruptions. 23262939 - Porcine dermis compared with polypropylene mesh for laparoscopic sacrocolpopexy: a rand... 9872519 - Gastric urease activity is inversely associated with the success of treatment for helic... 10655189 - Visual and anatomical results of surgery for long standing macular holes. 8278159 - Intraoperative suspension-recession technique for treatment of vertical strabismus in t... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European neurology Volume: 46 ISSN: 0014-3022 ISO Abbreviation: Eur. Neurol. Publication Date: 2001 |
Date Detail:
|
Created Date: 2001-11-26 Completed Date: 2002-01-25 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0150760 Medline TA: Eur Neurol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 210-4 Citation Subset: IM |
Copyright Information:
|
Copyright 2001 S. Karger AG, Basel |
Affiliation:
|
Department of Neurology, Justus Liebig University, Giessen, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antigens, CD / blood, drug effects* Brain / drug effects, pathology Disability Evaluation Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Interferon-beta / adverse effects, therapeutic use* Magnetic Resonance Imaging Male Multiple Sclerosis / blood, diagnosis, drug therapy* Prognosis Prospective Studies Receptors, Tumor Necrosis Factor / blood, drug effects* Receptors, Tumor Necrosis Factor, Type II |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD; 0/Receptors, Tumor Necrosis Factor; 0/Receptors, Tumor Necrosis Factor, Type II; 145155-23-3/interferon beta-1b; 145258-61-3/interferon beta 1a; 77238-31-4/Interferon-beta |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional s...
Next Document: Perception of lateral misarticulation and its physical correlates.